Advertisement
A vs TMO
Which Stock Would AI Choose? Agilent Technologies (A) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Agilent Technologies (A) delivered strong Q3 fiscal 2026 results with 8.1% revenue growth to $1.88 billion and raised full-year guidance, reflecting improving pharma and applied markets demand.
- Thermo Fisher Scientific (TMO) reported Q2 2026 revenue of $11.99 billion with 5% organic growth—the strongest pace since 2021—and raised its 2026 outlook amid strengthening biotech funding.
- A trades near $156 with a market capitalization of approximately $44 billion, while TMO trades near $651 with a market capitalization exceeding $230 billion, highlighting significant scale differences.
- Both companies operate in the life sciences tools sector and have benefited from recent earnings beats, though TMO received an analyst upgrade to Buy in September 2026.
- A offers higher operating margins and a dividend yield near 0.7%, while TMO provides broader end-market exposure and capital deployment through acquisitions and buybacks.
- Relative performance shows both stocks advancing in recent weeks on positive sentiment, with TMO demonstrating more pronounced analyst momentum.
Introduction
Agilent Technologies (A) and Thermo Fisher Scientific (TMO) represent two prominent players in the life sciences tools and diagnostics industry. Investors and traders often compare these stocks when evaluating exposure to pharmaceutical research, biotechnology funding cycles, and laboratory instrumentation demand. This analysis examines their recent financial results, stock behavior, and positioning within the current market environment. The comparison appeals to those seeking to understand relative performance, growth drivers, and risk profiles in a sector influenced by healthcare spending and innovation trends.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies (A) provides analytical instruments, diagnostics, and laboratory services primarily to pharmaceutical, biotechnology, and applied markets. In its third quarter of fiscal 2026, the company reported revenue of $1.88 billion, an 8.1% increase year over year, and exceeded earnings expectations. Management raised full-year fiscal 2026 guidance to revenue of $7.49 billion to $7.51 billion and non-GAAP EPS of $6.18 to $6.21. Recent market activity reflects positive sentiment following these results and the U.S. launch of the S540MD Slide Scanner System for digital pathology. The stock has traded near $156 in recent weeks, supported by analyst consensus targets around $170 and a quarterly dividend of $0.255 per share.
Thermo Fisher Scientific (TMO) Overview and Recent Performance
Thermo Fisher Scientific (TMO) offers a broad portfolio of life science solutions, analytical instruments, and biopharma services. For the second quarter of 2026, the company posted revenue of $11.99 billion, including 5% organic growth, with adjusted EPS rising 13% to $6.03. Management raised full-year 2026 guidance to revenue of $47.4 billion to $48.1 billion and adjusted EPS of $24.93 to $25.33. Recent market activity shows continued investor interest following the results and an upgrade to Buy by UBS with a $730 price target. The stock has traded near $651 amid improving demand signals in pharma and biotech end markets.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots page that features select AI trading bots optimized for prevailing market conditions. The platform offers hundreds of AI Trading Bots capable of trading thousands of different tickers, each employing distinct trading styles, strategies, timeframes, and performance statistics. Only the highest-performing and most suitable bots for current environments appear in the trending section, where users can review metrics such as historical returns, win rates, and drawdowns across various instruments. This resource provides traders with data-driven options for automated strategies. Explore the full selection on the Trending AI Robots page.
Head-to-Head Comparison
Agilent Technologies (A) focuses on specialized analytical chemistry and diagnostics tools, delivering higher operating margins around 27% in recent quarters. Thermo Fisher Scientific (TMO) operates at larger scale with diversified exposure across life sciences, diagnostics, and biopharma services, supporting broader revenue resilience. Recent momentum favors both on earnings strength, though TMO has attracted more explicit analyst upgrades. Risk factors include A’s greater sensitivity to specific end-market cycles such as applied materials, while TMO faces integration risks from acquisitions and higher leverage. Market sentiment remains constructive for the sector, with TMO benefiting from its size and recurring revenue streams compared with A’s more concentrated product focus.
Tickeron AI Verdict
Based on observable factors including earnings consistency, guidance raises, and analyst positioning in recent weeks, Tickeron’s AI models currently assign a modestly higher probability of favorable relative performance to Thermo Fisher Scientific (TMO). Its larger scale, diversified end markets, and recent Buy-side upgrades contribute to trend stability signals. Agilent Technologies (A) demonstrates solid margin expansion and product momentum but trails in breadth of coverage. Outcomes remain probabilistic and subject to evolving market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Buy and TMO is a Buy.
A | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 94 | 67 | |
SMR RATING 1..100 | 46 | 60 | |
PRICE GROWTH RATING 1..100 | 20 | 25 | |
P/E GROWTH RATING 1..100 | 25 | 16 | |
SEASONALITY SCORE 1..100 | 22 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (11) in the Biotechnology industry is in the same range as TMO (13) in the Medical Specialties industry. This means that A’s stock grew similarly to TMO’s over the last 12 months.
TMO's Profit vs Risk Rating (67) in the Medical Specialties industry is in the same range as A (94) in the Biotechnology industry. This means that TMO’s stock grew similarly to A’s over the last 12 months.
A's SMR Rating (46) in the Biotechnology industry is in the same range as TMO (60) in the Medical Specialties industry. This means that A’s stock grew similarly to TMO’s over the last 12 months.
A's Price Growth Rating (20) in the Biotechnology industry is in the same range as TMO (25) in the Medical Specialties industry. This means that A’s stock grew similarly to TMO’s over the last 12 months.
TMO's P/E Growth Rating (16) in the Medical Specialties industry is in the same range as A (25) in the Biotechnology industry. This means that TMO’s stock grew similarly to A’s over the last 12 months.
| A | TMO | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 70% | 4 days ago 65% |
| Stochastic ODDS (%) | 4 days ago 61% | 4 days ago 58% |
| Momentum ODDS (%) | 4 days ago 68% | 4 days ago 64% |
| MACD ODDS (%) | 4 days ago 69% | 4 days ago 66% |
| TrendWeek ODDS (%) | 4 days ago 64% | 4 days ago 62% |
| TrendMonth ODDS (%) | 4 days ago 61% | 4 days ago 62% |
| Advances ODDS (%) | 7 days ago 62% | 5 days ago 63% |
| Declines ODDS (%) | 19 days ago 63% | 21 days ago 62% |
| BollingerBands ODDS (%) | 4 days ago 73% | 4 days ago 64% |
| Aroon ODDS (%) | 4 days ago 63% | 4 days ago 58% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 3 FA rating(s) are green while TMO’s FA Score has 3 green FA rating(s).
- A’s FA Score: 3 green, 2 red.
- TMO’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 4 TA indicator(s) are bullish while TMO’s TA Score has 4 bullish TA indicator(s).
- A’s TA Score: 4 bullish, 4 bearish.
- TMO’s TA Score: 4 bullish, 4 bearish.
Price Growth
A (@Medical Specialties) experienced а +10.43% price change this week, while TMO (@Medical Specialties) price change was +3.62% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +2.23%. For the same industry, the average monthly price growth was +8.55%, and the average quarterly price growth was +50.66%.
Reported Earning Dates
A is expected to report earnings on Nov 30, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Medical Specialties (+2.23% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
A and
Correlation & Price change
A.I.dvisor indicates that over the last year, A has been closely correlated with TMO. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then TMO could also see price increases.
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.
| Ticker / NAME | Correlation To TMO | 1D Price Change % | ||
|---|---|---|---|---|
| TMO | 100% | -0.50% | ||
| A - TMO | 74% Closely correlated | -0.03% | ||
| DHR - TMO | 73% Closely correlated | +0.32% | ||
| RVTY - TMO | 70% Closely correlated | +0.29% | ||
| IQV - TMO | 69% Closely correlated | -1.69% | ||
| BRKR - TMO | 67% Closely correlated | +0.28% | ||
More | ||||